Stay updated on OpACIN-neo Optimal Combo Trial
Sign up to get notified when there's something new on the OpACIN-neo Optimal Combo Trial page.

Latest updates to the OpACIN-neo Optimal Combo Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange Detected- Added the Nat Med 2026 PRADO-trial publication: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis (Nat Med, 2026 Mar;32(3):952-963; Epub 2026 Jan 28). - Removed the earlier Nat Med ahead-of-print citation (Nat Med, 2026 Jan 28).SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-facing content changes were observed on the page.SummaryDifference0.0%

- Check32 days agoChange DetectedPage revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check61 days agoChange DetectedAdministrative updates: a new system revision (v3.4.2) is added, and older notices (including a funding-lapse alert and revision v3.4.1) are removed. These changes do not alter study details.SummaryDifference0.4%

- Check68 days agoChange DetectedAdded an administrative funding notice and a 2026 Nat Med publication citation to Publications, and updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedThe page now shows a glossary and includes minor text/capitalization updates (Last Update Submitted that Met QC Criteria vs met QC Criteria, No FEAR Act Data), and the Revision label updated to v3.4.0 from v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to OpACIN-neo Optimal Combo Trial
Enter your email address, and we'll notify you when there's something new on the OpACIN-neo Optimal Combo Trial page.